Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real‐world U.S. patients, 2003–2021
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18024 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2024. Written by Sally Tran and 7 co-authors. Institution: Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA. Major MEDLINE topics: Liver Cirrhosis, Liver Neoplasms, Carcinoma, Hepatocellular. Cited 11 times so far (Crossref); 39 references. Funded by: NCATS NIH HHS.
Abstract (original language)
Background
Adverse outcomes of cirrhosis remain a top priority.
Aims
We examined the distribution of cirrhosis causes, HCC incidence and mortality and related changes over time in a nationwide U.S. cohort.
Methods
A retrospective study of a national sample of commercially insured patients with cirrhosis from Optum's de‐identified Clinformatics® Data Mart Database (CDM).
Results
A total of 628,743 cirrhosis cases were identified with 45% having NAFLD, 19.5% HCV, and 16.3% ALD. African Americans had the highest rate of decompensation (60.6%), while Asians had the highest rate of HCC (2.4%), both p < 0.001. African Americans more frequently had HCV (28.4%) while Hispanic/Latinos more frequently had NAFLD (49.2%, p < 0.001). Patients in the 2014–2021 cohort were significantly older (63.0 ± 12.8 vs. 57.0 ± 14.3), less frequently decompensated (54.5% vs. 58.3%) but more frequently had HCC (1.7% vs. 0.6%) and NAFLD (46.5% vs. 44.2%), all p < 0.001. The overall annual incidence of HCC was 0.76% (95% CI: 0.75–0.77) with a 5‐year cumulative incidence of 4.03% (95% CI: 3.98–4.09), with significant variation by sex, race/ethnicity, and cirrhosis aetiology. The overall median years of survival were 11.4 (95% CI: 11.3–11.5) with a 5‐year cumulative survival of 73.4% (95% CI: 73.3%–73.6%), also with significant disparities in similar subgroups (lowest in cryptogenic cirrhosis and worse in 2014–2021 vs. 2003–2013). The 2014–2021 period was independently associated with worse survival (aHR: 1.14, 95% CI: 1.08–1.20).
Conclusions
HCC incidence and survival vary by aetiology among patients with cirrhosis, with cryptogenic cirrhosis having the lowest survival and lower survival in the more recent time period.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
- Department of Epidemiology and Population Health, Stanford University School of Medicine, Palo Alto, California, USA.
- Division of General Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Division of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
ORCID profiles: YeeHui Yeo, Mindie H Nguyen
Funding
- NCATS NIH HHS
Cite
APA
Tran, S., Zou, B., Lee, K., Kam, L., Yeo, Y., Henry, L., Cheung, R., & Nguyen, M. H. (2024). Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real‐world U.S. patients, 2003–2021. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18024
Vancouver
Tran S, Zou B, Lee K, Kam L, Yeo Y, Henry L, et al. Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real‐world U.S. patients, 2003–2021. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18024
BibTeX
@article{Tran2024,
author = {Tran, Sally and Zou, Biyao and Lee, KeeSeok and Kam, Leslie and Yeo, YeeHui and Henry, Linda and Cheung, Ramsey and Nguyen, Mindie H},
title = {Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real‐world U.S. patients, 2003–2021},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18024}
}
EUVIMED